United Services Automobile Association lessened its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,314 shares of the biopharmaceutical company’s stock after selling 5,144 shares during the quarter. United Services Automobile Association’s holdings in Alexion Pharmaceuticals were worth $5,411,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Alexion Pharmaceuticals by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after purchasing an additional 211,960 shares during the period. BlackRock Inc. increased its position in Alexion Pharmaceuticals by 1.2% in the second quarter. BlackRock Inc. now owns 16,225,615 shares of the biopharmaceutical company’s stock worth $2,125,230,000 after buying an additional 199,298 shares during the period. Nuveen Asset Management LLC increased its position in Alexion Pharmaceuticals by 57,650.8% in the second quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock worth $476,393,000 after buying an additional 3,630,846 shares during the period. Bank of America Corp DE increased its position in Alexion Pharmaceuticals by 0.7% in the second quarter. Bank of America Corp DE now owns 2,078,585 shares of the biopharmaceutical company’s stock worth $272,253,000 after buying an additional 13,426 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its stake in Alexion Pharmaceuticals by 6.9% in the second quarter. UBS Asset Management Americas Inc. now owns 1,564,135 shares of the biopharmaceutical company’s stock valued at $204,870,000 after buying an additional 100,509 shares during the last quarter. Hedge funds and other institutional investors own 91.53% of the company’s stock.
Shares of Alexion Pharmaceuticals stock opened at $112.79 on Wednesday. The stock’s fifty day moving average is $110.52 and its 200-day moving average is $110.30. The company has a quick ratio of 3.45, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $24.23 billion, a PE ratio of 15.91, a price-to-earnings-growth ratio of 0.77 and a beta of 1.64. Alexion Pharmaceuticals, Inc. has a 12-month low of $94.59 and a 12-month high of $141.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.47 by $0.32. The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The company’s revenue was up 23.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.02 EPS. Analysts expect that Alexion Pharmaceuticals, Inc. will post 9.44 EPS for the current year.
Several equities analysts have recently commented on ALXN shares. Evercore ISI restated a “buy” rating and set a $145.00 price target on shares of Alexion Pharmaceuticals in a research report on Sunday, November 17th. SunTrust Banks assumed coverage on shares of Alexion Pharmaceuticals in a report on Tuesday, November 12th. They issued a “buy” rating and a $125.00 price objective on the stock. Bank of America initiated coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, October 17th. They issued a “buy” rating on the stock. Morgan Stanley lowered shares of Alexion Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $170.00 to $128.00 in a research note on Tuesday, December 17th. Finally, ValuEngine upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $154.16.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
See Also: What is quantitative easing?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.